A

Attovia Therapeutics

ATTOPro tracking

Attovia Therapeutics, Inc. · Nasdaq · Immune-disease biotechnology · Research source · 424B4 · Research as of 2026/08/05 · Latest filing · 10-Q · 2026-11-09 SEC ↗ · SEC checked 2026-11-21

SEC
Saved research available · 424B4

Attovia priced its IPO at $17.00 per share for 17.0 million shares, with Nasdaq listing approved under ATTO.

Research source · 424B4 · Research as of 2026/08/05Latest analyzed filing · 424B4 · 2026-08-05

Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.

SummaryWATCHReport source · 424B4

Newly listed — review valuation, deal quality and post-IPO supply before acting

A clinical-stage developer of ATTOBODY-based treatments for immune-mediated diseases. The IPO priced at $17.00 and raised $289.00M.

Full source-backed summary

A clinical-stage developer of ATTOBODY-based treatments for immune-mediated diseases. The IPO priced at $17.00 and raised $289.00M. The latest market-value reference is $895.00M; reported revenue is $1.35M and net result is $(64.13M). The offer figures are reconciled to the final prospectus.

Total revenue$1,350,000FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net loss($60,627,000)FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities($59,199,000)FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Voting controlNo controlling party conclusion availableNot separately disclosed voting
Next disclosed checkpointFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
Business and development direction

A clinical-stage developer of ATTOBODY-based treatments for immune-mediated diseases.

Current business

Immune-disease biotechnology100%

Future development

Future direction not yet disclosed

DECISION DRIVERS

Key risks

High

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

High

Risk 2

The latest reported period remains loss-making.

High

Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

NEXT EVENTFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
LATEST EVIDENCE424B42026/08/05
LISTING CHECKPOINT2026-08-05Nasdaq
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualityThis saved report has no compatible source inputs for this calculation. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
CONFIRMED
#InstitutionUnderwriting allocationRatio · calculatedShares
1Morgan Stanley & Co. LLC40.00%6,800,000 shares
2Leerink Partners LLC28.00%4,760,000 shares
3Citigroup Global Markets Inc.19.00%3,230,000 shares
4RBC Capital Markets, LLC7.00%1,190,000 shares
5LifeSci Capital LLC6.00%1,020,000 shares

Ratio = institution commitment ÷ complete source-table total (17,000,000 shares) × 100.

Source and calculation

Allocation ratios are calculated from each reported commitment and the complete total in the same source table; they are not ownership or fee percentages.

Underwriting purchase commitments as disclosed; shares; source class retained in the column header; source column: Number ofShares

Number ofShares

SEC table 559 row 9; source 1584577:1588786; SHA256 b9bb445c1a557156d9605423c83bb9f7a874a1f3ce9d6b2a289496d071ee0de7

Morgan Stanley & Co. LLC: 6800000 / 17000000 × 100

Leerink Partners LLC: 4760000 / 17000000 × 100

Citigroup Global Markets Inc.: 3230000 / 17000000 × 100

RBC Capital Markets, LLC: 1190000 / 17000000 × 100

LifeSci Capital LLC: 1020000 / 17000000 × 100

Source · 424B4 ↗

Underwriting terms

Underwriting terms
MeasureReported valueUnit
Underwriting discount per share$1.19$ / share
Total underwriting discount$20,230,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Underwriting discount per share

Base prospectus offering; cover per-share and total columns

SEC table 1 row 4; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Total underwriting discount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 4; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗

IPO CAPITAL QUALITY

Offering price $ / share$17
Gross offering amount $$289,000,000
Shares offered Shares17,000,000
Issuer proceeds before expenses $$268,770,000
Basis and evidence

No estimate is substituted for missing offer terms.

Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.

Offering structure

Offering terms
MeasureReported valueUnit
Shares offered17,000,000Shares
Offering price$17$ / share
Gross offering amount$289,000,000$
Source and calculation

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

Shares offered

Prospectus offering table; stated base scenario and source conditions

SEC table 40 row 2; source 92131:97654; SHA256 420bd74618131df6b7ffaeb4006cd07d0ca5a66059d442ab11fdba29f9e44553 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Gross offering amount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 3; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗
IPO investors$289.00Mgross offer size
Issuer / selling holdersSee 424Bprimary-secondary split
Reported revenue$1.35MNot meaningful
Net result$(64.13M)latest reported basis
Future supplyLock-upreview holder-specific terms

Proceeds and intended uses

Proceeds and intended uses
MeasureReported valueUnit
Issuer proceeds before expenses$268,770,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Issuer proceeds before expenses

Base prospectus offering; cover per-share and total columns

SEC table 1 row 5; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗

Dilution and valuation

IPO price$17Final
Basic post-offer≈ 43.029M
Equity value≈ $731.4933M
Dilution and valuation
CalculationSharesValueReference
Base post-offer valuation≈ 43.029M≈ $731.4933M
Derived calculationFinalshares · $Basis and evidence 10 ↗
Post-offer shares — base/no option43,029,017—
Reported sourcePost-offer · BasesharesBasis and evidence 8 ↗
Post-offer shares — full option45,579,017—
Reported sourcePost-offer · Full optionsharesBasis and evidence 8 ↗
Capitalization shares — actual4,511,041—
Reported sourceCommon stock; actualsharesBasis and evidence 3 ↗
Capitalization shares — pro forma26,029,017—
Reported sourceCommon stock; pro formasharesBasis and evidence 4 ↗
Capitalization shares — pro forma as adjusted43,029,017—
Reported sourceCommon stock; pro forma as adjustedsharesBasis and evidence 5 ↗
Shares offered17,000,000—
Reported sourcesharesBasis and evidence 6 ↗
Offering price—$17
Reported sourceFinal$/shareBasis and evidence 7 ↗
Gross offering amount—$289,000,000
Reported source$Basis and evidence 7 ↗
Basis and evidence ↗
Basis and evidence 1

Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 40 row 6 columns 3; share summary; label column 1; source 92131:97654; SHA256 420bd74618131df6b7ffaeb4006cd07d0ca5a66059d442ab11fdba29f9e44553 ↗

Basis and evidence 2

Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 40 row 6 columns 3; share summary; label column 1; source 92131:97654; SHA256 420bd74618131df6b7ffaeb4006cd07d0ca5a66059d442ab11fdba29f9e44553 ↗

Basis and evidence 3

Capitalization share count; source stage: actual; Common stock, par value $0.0001 per share; 284,023,000 shares authorized, 4,511,041 shares issued and outstanding, actual; 500,000,000 shares authorized, 26,029,017 shares issued and outstanding, pro forma; 500,000,000 shares authorized, 43,029,017 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 290 row 10 columns 1; share summary; label column 1; source 674011:687812; SHA256 f734c212660166f1a3b9a0e9f2cf68aa3fff22ee9c13a5620832b65697926369 ↗

Basis and evidence 4

Capitalization share count; source stage: pro forma; Common stock, par value $0.0001 per share; 284,023,000 shares authorized, 4,511,041 shares issued and outstanding, actual; 500,000,000 shares authorized, 26,029,017 shares issued and outstanding, pro forma; 500,000,000 shares authorized, 43,029,017 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 290 row 10 columns 1; share summary; label column 1; source 674011:687812; SHA256 f734c212660166f1a3b9a0e9f2cf68aa3fff22ee9c13a5620832b65697926369 ↗

Basis and evidence 5

Capitalization share count; source stage: pro forma as adjusted; Common stock, par value $0.0001 per share; 284,023,000 shares authorized, 4,511,041 shares issued and outstanding, actual; 500,000,000 shares authorized, 26,029,017 shares issued and outstanding, pro forma; 500,000,000 shares authorized, 43,029,017 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 290 row 10 columns 1; share summary; label column 1; source 674011:687812; SHA256 f734c212660166f1a3b9a0e9f2cf68aa3fff22ee9c13a5620832b65697926369 ↗

Basis and evidence 6

Prospectus offering table; stated base scenario and source conditions

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

SEC table 40 row 2; source 92131:97654; SHA256 420bd74618131df6b7ffaeb4006cd07d0ca5a66059d442ab11fdba29f9e44553 ↗

Basis and evidence 7

Base prospectus offering; cover per-share and total columns

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

SEC table 1 row 3; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗

Basis and evidence 8

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Offering price: $17

Exact input · Post-offer shares — base/no option: 43,029,017

Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — full option: 45,579,017

SEC table 1 row 3; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗

SEC table 40 row 6 columns 3; share summary; label column 1; source 92131:97654; SHA256 420bd74618131df6b7ffaeb4006cd07d0ca5a66059d442ab11fdba29f9e44553 ↗

SEC valuation primary issuer cover; source 1277:1480; SHA256 334859f8355bb73f5c72728ae40bc4e4994827af452df61b82d301d28089c1d3 ↗

SEC valuation summary conditions; source 87498:92060; SHA256 54ef6306950b6a03c175e38c9a3bc0dd470537721f85a2f57dfcade9ff8ed05a ↗

SEC valuation summary conditions; source 97655:136535; SHA256 d6b13be8b377305cba1a9bc656e459b89e9d3206e801e39a8189b158713bc20f ↗

Basis and evidence 10

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 43,029,017 shares (or 45,579,017 shares, if the underwriters exercise their over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — base/no option: 43,029,017

Exact input · Offering price: $17

SEC table 1 row 3; source 3062:5754; SHA256 858bad04ffdb44b28bdcc16e85880f0b8bb111f8fe961ad907d6e54e627e5e2b ↗

SEC table 40 row 6 columns 3; share summary; label column 1; source 92131:97654; SHA256 420bd74618131df6b7ffaeb4006cd07d0ca5a66059d442ab11fdba29f9e44553 ↗

SEC valuation primary issuer cover; source 1277:1480; SHA256 334859f8355bb73f5c72728ae40bc4e4994827af452df61b82d301d28089c1d3 ↗

SEC valuation summary conditions; source 87498:92060; SHA256 54ef6306950b6a03c175e38c9a3bc0dd470537721f85a2f57dfcade9ff8ed05a ↗

SEC valuation summary conditions; source 97655:136535; SHA256 d6b13be8b377305cba1a9bc656e459b89e9d3206e801e39a8189b158713bc20f ↗

Share-count comparison

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Offering completion · $17 × ≈ 43.029M shares · Final

Implied equity value≈ $731.4933MPrice × post-offer shares
Post-offer shares≈ 43.029MShare count, not tradable float
Existing-holder ownership reduction0.0%Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.

Base post-offer shares

Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.

Equity value

Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.

Share-count change

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Alternative scenarios

Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.

Sensitivity

The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

Prior saved context

These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.

IPO price · 17.000M · $289.00M · $17.00

Latest shares outstanding · 43.03M · $895.00M · Market snapshot

Revenue reference · — · $1.35M · Not meaningful

Net-result reference · — · $(64.13M) · Loss-making

$17 × 43,029,017 = $731,493,289 [summary-table-40-base-6-price, summary-table-40-base-6-post]

Exact calculation · Derived whole-issuer equity value: $731,493,289

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesComparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗
CONTROLLING PARTYNo controlling party conclusion available

Latest available filing

Economic
~39.5%*
As of
2026/08/05
!Review the beneficial-ownership table and voting rights togetherView source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · Attovia Therapeutics
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
Frazier Life Sciences XI, L.P.Beneficial shares5,565,980——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Alamar HoldCo, LLCBeneficial shares3,229,279——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
venBio Global Strategic Fund IV, L.P.Beneficial shares3,799,016——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Entities affiliated with Goldman Sachs & Co. LLCBeneficial shares2,435,641——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Deep Track Biotechnology Master Fund, LtdBeneficial shares1,957,139——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Tao FuBeneficial shares893,456——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Petter VeibyBeneficial shares212,258——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Hubert ChenBeneficial shares153,279——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Mitchell GoldBeneficial shares41,873——
Number ofSharesBeneficiallyOwnedDisclosedEvidence
Angie YouBeneficial shares59,490——
Number ofSharesBeneficiallyOwned; —; —; —; —DisclosedEvidence
All executive officers and directors as a group (12 persons)Beneficial shares1,687,208——
Number ofSharesBeneficiallyOwned; —; —; —; —DisclosedEvidence
Frazier Life Sciences XI, L.P.Beneficial ownership—21.3%Beneficial—
Percentage ofSharesBeneficiallyOwned; BeforeOfferingDisclosedEvidence
Frazier Life Sciences XI, L.P.Beneficial ownership—12.9%Beneficial—
Percentage ofSharesBeneficiallyOwned; AfterOfferingDisclosedEvidence
Alamar HoldCo, LLCBeneficial ownership—12.4%Beneficial—
Percentage ofSharesBeneficiallyOwned; BeforeOfferingDisclosedEvidence
Alamar HoldCo, LLCBeneficial ownership—7.5%Beneficial—
Percentage ofSharesBeneficiallyOwned; AfterOfferingDisclosedEvidence
venBio Global Strategic Fund IV, L.P.Beneficial ownership—14.6%Beneficial—
Percentage ofSharesBeneficiallyOwned; BeforeOfferingDisclosedEvidence
venBio Global Strategic Fund IV, L.P.Beneficial ownership—8.8%Beneficial—
Percentage ofSharesBeneficiallyOwned; AfterOfferingDisclosedEvidence
Entities affiliated with Goldman Sachs & Co. LLCBeneficial ownership—9.3%Beneficial—
Percentage ofSharesBeneficiallyOwned; BeforeOfferingDisclosedEvidence
Entities affiliated with Goldman Sachs & Co. LLCBeneficial ownership—5.7%Beneficial—
Percentage ofSharesBeneficiallyOwned; AfterOfferingDisclosedEvidence
Deep Track Biotechnology Master Fund, LtdBeneficial ownership—7.5%Beneficial—
Percentage ofSharesBeneficiallyOwned; BeforeOfferingDisclosedEvidence
Deep Track Biotechnology Master Fund, LtdBeneficial ownership—4.5%Beneficial—
Percentage ofSharesBeneficiallyOwned; AfterOfferingDisclosedEvidence
Tao FuBeneficial ownership—3.4%Beneficial—
Percentage ofSharesBeneficiallyOwned; BeforeOfferingDisclosedEvidence
Tao FuBeneficial ownership—2.1%Beneficial—
Percentage ofSharesBeneficiallyOwned; AfterOfferingDisclosedEvidence
All executive officers and directors as a group (12 persons)Beneficial ownership—6.3%Beneficial—
Percentage ofSharesBeneficiallyOwned; BeforeOffering; —; —; —; —DisclosedEvidence
All executive officers and directors as a group (12 persons)Beneficial ownership—3.9%Beneficial—
Percentage ofSharesBeneficiallyOwned; AfterOffering; —; —; —; —DisclosedEvidence
Frazier Life Sciences XI, L.P.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
venBio Global Strategic Fund IV, L.P.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, together with their affiliatesOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Frazier Life Sciences XI, L.P.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
venBio Global Strategic Fund IV, L.P.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Deep Track Biotechnology Master Fund, LtdOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Frazier Life Sciences XI, L.P.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
venBio Global Strategic Fund IV, L.P.Ownership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, together with their affiliatesOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
entities with which certain of our directors are affiliatedOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partitionDisclosedEvidence
individuals and entities associated with Fenwick & West LLPOwnership as disclosed—<0.001%Beneficial—
Source statement; <; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our common stock; not an additive ownership partitionDisclosedEvidence
common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicableDisclosedEvidence
Source and calculation ↗
Frazier Life Sciences XI, L.P. · Frazier Life Sciences XI, L.P. — Beneficial shares · 5,565,980

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Frazier Life Sciences XI, L.P.(1)

0001193125-26-334997 · SEC table 510 row 5 columns 4; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:3 ↗

Alamar HoldCo, LLC · Alamar HoldCo, LLC — Beneficial shares · 3,229,279

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Alamar HoldCo, LLC(2)

0001193125-26-334997 · SEC table 510 row 6 columns 4; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:3 ↗

venBio Global Strategic Fund IV, L.P. · venBio Global Strategic Fund IV, L.P. — Beneficial shares · 3,799,016

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: venBio Global Strategic Fund IV, L.P.(3)

0001193125-26-334997 · SEC table 510 row 7 columns 4; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:3 ↗

Entities affiliated with Goldman Sachs & Co. LLC · Entities affiliated with Goldman Sachs & Co. LLC — Beneficial shares · 2,435,641

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Entities affiliated with Goldman Sachs & Co. LLC(4)

0001193125-26-334997 · SEC table 510 row 8 columns 4; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:3 ↗

Deep Track Biotechnology Master Fund, Ltd · Deep Track Biotechnology Master Fund, Ltd — Beneficial shares · 1,957,139

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Deep Track Biotechnology Master Fund, Ltd(5)

0001193125-26-334997 · SEC table 510 row 9 columns 4; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:3 ↗

Tao Fu · Tao Fu — Beneficial shares · 893,456

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Tao Fu(6)

0001193125-26-334997 · SEC table 510 row 12 columns 4; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:3 ↗

Petter Veiby · Petter Veiby — Beneficial shares · 212,258

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Petter Veiby(7)

0001193125-26-334997 · SEC table 510 row 13 columns 4; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:3 ↗

Hubert Chen · Hubert Chen — Beneficial shares · 153,279

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Hubert Chen(8)

0001193125-26-334997 · SEC table 510 row 14 columns 4; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:3 ↗

Mitchell Gold · Mitchell Gold — Beneficial shares · 41,873

Exact source ownership column: Number ofSharesBeneficiallyOwned; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; source holder: Mitchell Gold(9)

0001193125-26-334997 · SEC table 510 row 15 columns 4; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:3 ↗

Angie You · Angie You — Beneficial shares · 59,490

Exact source ownership column: Number ofSharesBeneficiallyOwned; —; —; —; —; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; —; —; —; —; source holder: Angie You(10)

0001193125-26-334997 · SEC table 511 row 8 columns 4; source 1469835:1476296; SHA256 1e1bc4be258b84e00f6229807bbedf4add6231ccc360a3a0ee71900235f530b7; ownership header cells 2:3,4:4,5:4,6:4,7:4 ↗

All executive officers and directors as a group (12 persons) · All executive officers and directors as a group (12 persons) — Beneficial shares · 1,687,208

Exact source ownership column: Number ofSharesBeneficiallyOwned; —; —; —; —; holders may overlap; not an additive partition

Raw source column: Number ofSharesBeneficiallyOwned; —; —; —; —; source holder: All executive officers and directors as a group (12 persons)(11)

0001193125-26-334997 · SEC table 511 row 9 columns 4; source 1469835:1476296; SHA256 1e1bc4be258b84e00f6229807bbedf4add6231ccc360a3a0ee71900235f530b7; ownership header cells 2:3,4:4,5:4,6:4,7:4 ↗

Frazier Life Sciences XI, L.P. · Frazier Life Sciences XI, L.P. — Beneficial ownership · 21.3%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Frazier Life Sciences XI, L.P.(1)

0001193125-26-334997 · SEC table 510 row 5 columns 8,9; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:2 ↗

Frazier Life Sciences XI, L.P. · Frazier Life Sciences XI, L.P. — Beneficial ownership · 12.9%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Frazier Life Sciences XI, L.P.(1)

0001193125-26-334997 · SEC table 510 row 5 columns 12,13; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:5 ↗

Alamar HoldCo, LLC · Alamar HoldCo, LLC — Beneficial ownership · 12.4%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Alamar HoldCo, LLC(2)

0001193125-26-334997 · SEC table 510 row 6 columns 8,9; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:2 ↗

Alamar HoldCo, LLC · Alamar HoldCo, LLC — Beneficial ownership · 7.5%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Alamar HoldCo, LLC(2)

0001193125-26-334997 · SEC table 510 row 6 columns 12,13; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:5 ↗

venBio Global Strategic Fund IV, L.P. · venBio Global Strategic Fund IV, L.P. — Beneficial ownership · 14.6%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: venBio Global Strategic Fund IV, L.P.(3)

0001193125-26-334997 · SEC table 510 row 7 columns 8,9; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:2 ↗

venBio Global Strategic Fund IV, L.P. · venBio Global Strategic Fund IV, L.P. — Beneficial ownership · 8.8%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: venBio Global Strategic Fund IV, L.P.(3)

0001193125-26-334997 · SEC table 510 row 7 columns 12,13; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:5 ↗

Entities affiliated with Goldman Sachs & Co. LLC · Entities affiliated with Goldman Sachs & Co. LLC — Beneficial ownership · 9.3%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Entities affiliated with Goldman Sachs & Co. LLC(4)

0001193125-26-334997 · SEC table 510 row 8 columns 8,9; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:2 ↗

Entities affiliated with Goldman Sachs & Co. LLC · Entities affiliated with Goldman Sachs & Co. LLC — Beneficial ownership · 5.7%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Entities affiliated with Goldman Sachs & Co. LLC(4)

0001193125-26-334997 · SEC table 510 row 8 columns 12,13; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:5 ↗

Deep Track Biotechnology Master Fund, Ltd · Deep Track Biotechnology Master Fund, Ltd — Beneficial ownership · 7.5%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Deep Track Biotechnology Master Fund, Ltd(5)

0001193125-26-334997 · SEC table 510 row 9 columns 8,9; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:2 ↗

Deep Track Biotechnology Master Fund, Ltd · Deep Track Biotechnology Master Fund, Ltd — Beneficial ownership · 4.5%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Deep Track Biotechnology Master Fund, Ltd(5)

0001193125-26-334997 · SEC table 510 row 9 columns 12,13; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:5 ↗

Tao Fu · Tao Fu — Beneficial ownership · 3.4%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; source holder: Tao Fu(6)

0001193125-26-334997 · SEC table 510 row 12 columns 8,9; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:2 ↗

Tao Fu · Tao Fu — Beneficial ownership · 2.1%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; source holder: Tao Fu(6)

0001193125-26-334997 · SEC table 510 row 12 columns 12,13; source 1458952:1469339; SHA256 388ab79d7f47b426c85ba8b245ed18bcdc3e88c6a57920d1274a1a9994f1b4c2; ownership header cells 2:6,3:5 ↗

All executive officers and directors as a group (12 persons) · All executive officers and directors as a group (12 persons) — Beneficial ownership · 6.3%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; —; —; —; —; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; BeforeOffering; —; —; —; —; source holder: All executive officers and directors as a group (12 persons)(11)

0001193125-26-334997 · SEC table 511 row 9 columns 8,9; source 1469835:1476296; SHA256 1e1bc4be258b84e00f6229807bbedf4add6231ccc360a3a0ee71900235f530b7; ownership header cells 2:6,3:2,4:8,5:8,6:8,7:8 ↗

All executive officers and directors as a group (12 persons) · All executive officers and directors as a group (12 persons) — Beneficial ownership · 3.9%

Exact source ownership column: Percentage ofSharesBeneficiallyOwned; AfterOffering; —; —; —; —; holders may overlap; not an additive partition

Raw source column: Percentage ofSharesBeneficiallyOwned; AfterOffering; —; —; —; —; source holder: All executive officers and directors as a group (12 persons)(11)

0001193125-26-334997 · SEC table 511 row 9 columns 12,13; source 1469835:1476296; SHA256 1e1bc4be258b84e00f6229807bbedf4add6231ccc360a3a0ee71900235f530b7; ownership header cells 2:6,3:5,4:12,5:12,6:12,7:12 ↗

Frazier Life Sciences XI, L.P. · Frazier Life Sciences XI, L.P. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of shares of our Series A Preferred Stock purchased by Frazier Life Sciences XI, L.P., which beneficially owns more than 5% of our outstanding capital stock. James Topper, a member of our board of directors, is affiliated with Frazier Life Sciences XI, L.P.

0001193125-26-334997 · SEC ownership paragraph; source 1431959:1432339; SHA256 e0a6fcac370377dc03b7730f2e8df1456d88b48e82ae52667b6f231e8cc97d0a ↗

venBio Global Strategic Fund IV, L.P. · venBio Global Strategic Fund IV, L.P. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of shares of our Series A Preferred Stock purchased by venBio Global Strategic Fund IV, L.P., which beneficially owns more than 5% of our outstanding capital stock. Aaron Royston, a member of our board of directors, is affiliated with venBio Global Strategic Fund IV, L.P.

0001193125-26-334997 · SEC ownership paragraph; source 1432619:1433014; SHA256 ed76c0d964cdbf71762e7d71a9464bddea335c9c51ed1834cbe34e5a2a88dac8 ↗

West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, together with their affiliates · West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, together with their affiliates — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of shares of our Series B Preferred Stock purchased by West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, which together with their affiliates, hold more than 5% of our outstanding capital stock. Colin Walsh, a member of our board of directors, is affiliated with Goldman Sachs & Co. LLC.

0001193125-26-334997 · SEC ownership paragraph; source 1437916:1438466; SHA256 7028dd3258e1e1bd704f3927b08beaf55be76bc86e9417f09035cd0334fce052 ↗

Frazier Life Sciences XI, L.P. · Frazier Life Sciences XI, L.P. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of shares of our Series B Preferred Stock purchased by Frazier Life Sciences XI, L.P., which beneficially owns more than 5% of our outstanding capital stock. James Topper, a member of our board of directors, is affiliated with Frazier Life Sciences XI, L.P.

0001193125-26-334997 · SEC ownership paragraph; source 1438746:1439126; SHA256 0558bbc1d41774bff7e5a891ea695e561dc96e7e7f45b2696e930f443e0f3c5f ↗

venBio Global Strategic Fund IV, L.P. · venBio Global Strategic Fund IV, L.P. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of shares of our Series B Preferred Stock purchased by venBio Global Strategic Fund IV, L.P., which beneficially owns more than 5% of our outstanding capital stock. Aaron Royston, a member of our board of directors, is affiliated with venBio Global Strategic Fund IV, L.P.

0001193125-26-334997 · SEC ownership paragraph; source 1439406:1439801; SHA256 54e51ee4e39da70e19c3b57dbbf9cad6fb6201f153bb2981302b16166edf5788 ↗

Deep Track Biotechnology Master Fund, Ltd · Deep Track Biotechnology Master Fund, Ltd — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of shares of our Series C Preferred Stock purchased by Deep Track Biotechnology Master Fund, Ltd, which beneficially owns more than 5% of our outstanding capital stock. Rebecca Luse, a former member of our board of directors, is affiliated with Deep Track Biotechnology Master Fund, Ltd. Ms. Luse resigned from our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.

0001193125-26-334997 · SEC ownership paragraph; source 1445938:1446502; SHA256 40e358a3c34dde242d3388cb0d77fa6f6f2a89501e19e903326e58f01905864f ↗

Frazier Life Sciences XI, L.P. · Frazier Life Sciences XI, L.P. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of shares of our Series C Preferred Stock purchased by Frazier Life Sciences XI, L.P., which beneficially owns more than 5% of our outstanding capital stock. James Topper, a member of our board of directors, is affiliated with Frazier Life Sciences XI, L.P.

0001193125-26-334997 · SEC ownership paragraph; source 1446782:1447162; SHA256 b7365f07700bcd70cc1c403de300f4fce176f9d550e8f4a174d94120cc89c983 ↗

venBio Global Strategic Fund IV, L.P. · venBio Global Strategic Fund IV, L.P. — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of shares of our Series C Preferred Stock purchased by venBio Global Strategic Fund IV, L.P., which beneficially owns more than 5% of our outstanding capital stock. Aaron Royston, a member of our board of directors, is affiliated with venBio Global Strategic Fund IV, L.P.

0001193125-26-334997 · SEC ownership paragraph; source 1447442:1447837; SHA256 bc5abf3dca8029ac2393a2ad9c6183d9b8183b25762aae8d60642e6dacd70f7d ↗

West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, together with their affiliates · West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, together with their affiliates — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of shares of our Series C Preferred Stock purchased by West Street Life Sciences I, LP, WSLS Offshore Investments, SLP, WSLS Emp Onshore Investments, L.P., WSLS Emp Offshore Investments, L.P. and Broad Street Principal Investments LLC, which together with their affiliates, hold more than 5% of our outstanding capital stock. Colin Walsh, a member of our board of directors, is affiliated with Goldman Sachs & Co. LLC.

0001193125-26-334997 · SEC ownership paragraph; source 1448117:1448667; SHA256 661afa3073211fb5240eac1919788a519f6076295026094f4d87f948f57854b1 ↗

entities with which certain of our directors are affiliated · entities with which certain of our directors are affiliated — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partition

In connection with our Series C Preferred Stock financing, we entered into the IRA with certain holders of our redeemable convertible preferred stock, including entities with which certain of our directors are affiliated and who hold more than 5% of our outstanding common stock. Under the IRA, these stockholders are entitled to rights with respect to the registration of their shares under the Securities Act following this offering, and the registration rights provisions included in the IRA will not terminate as a result of this offering. See the section titled “Description of Capital Stock—Registration Rights” for additional information.

0001193125-26-334997 · SEC ownership paragraph; source 1448823:1449613; SHA256 a3ddf6b8eed629e5a82deeae9358c7a132088a4d1e18e58ff3a8dc392903e936 ↗

individuals and entities associated with Fenwick & West LLP · individuals and entities associated with Fenwick & West LLP — Ownership as disclosed · <0.001%

Source statement; <; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our common stock; not an additive ownership partition

The validity of the shares of our common stock offered by this prospectus will be passed upon for us by Fenwick & West LLP, San Francisco, California. As of the date of this prospectus, individuals and entities associated with Fenwick & West LLP beneficially own an aggregate of less than 0.001% of our common stock. Cooley LLP, San Diego, California is acting as counsel for the underwriters in connection with this offering.

0001193125-26-334997 · SEC ownership paragraph; source 1660753:1661325; SHA256 5b656f5a036af84851766422954e2e1c582d752d7f8db08d8c66e9f7ec1d1160 ↗

common stock · common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of incorporation will establish a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Source context: The following description summarizes the most important terms of our capital stock, as will be in effect following this offering. Because it is only a summary, it does not contain all the information that may be important to you. We expect to adopt a restated certificate of incorporation and restated bylaws that will become effective immediately prior to the completion of this offering, and this description summarizes provisions that are expected to be included in these documents. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.

0001193125-26-334997 · SEC ownership excerpt; source 1489537:1490358; SHA256 448c433b16134b4247d0da4d2bd80942f768b23773ef2258be668c6093c22cab; context source 1486012:1486886; SHA256 75015e9c415e8e7b3a24b3bd6cbd8a611bd0d1c09cc6ca87724bef400253f232 ↗

Saved control snapshot

The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.

Saved control snapshot
Holder / measureSharesOwnershipVoting rightsReference
Existing holdersMajor ownership group—~60.5%*—
2026/08/05Latest available filing424B4 ↗
Other disclosed classesMajor ownership group—See filing—
2026/08/05Latest available filing424B4 ↗
IPO sharesPublic / new investors—17.000M—
2026/08/05Latest available filing424B4 ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

POTENTIAL SUPPLY PRESSURERequires holder-level review

IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.

Initial float
17.000M
Restricted / potential supply
43.03M
Multiple
See filing
Increase
See filing

Share supply

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
We, our officers, directors and all of our stockholdersAfter date of this prospectus · Source conditions apply180 days
Each of our officers, directors and all of our stockholdersAfter date of this prospectus · Source conditions apply180 days
Source and calculation
We, our officers, directors and all of our stockholders

We, our officers, directors and all of our stockholders have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.”

SEC lock-up paragraph; source 1533482:1534829; SHA256 8122d6937abadac01ad2b04cd9a3dfb34465ef286277ea82e2c3670b323d8c03 ↗
Each of our officers, directors and all of our stockholders

Based on 26,029,017 shares of our common stock outstanding as of March 31, 2026, including the automatic conversion of all shares of our outstanding redeemable convertible preferred stock as of March 31, 2026 into an aggregate of 21,517,976 shares of our common stock in connection with the completion of this offering, upon completion of this offering, we will have a total of 43,029,017 shares of common stock outstanding. Of these shares, only the 17,000,000 shares of common stock sold in this offering, or 19,550,000 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Morgan Stanley & Co. LLC, Leerink Partners LLC, Citigroup Global Markets Inc. and RBC Capital Markets, LLC may, in their sole discretion, permit our officers, directors and other stockholders to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on 26,029,017 shares outstanding as of March 31, 2026, approximately up to an additional 26,749,461 shares of common stock will be eligible for sale in the public market, approximately 15,044,561 of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act.

SEC lock-up paragraph; source 603838:605892; SHA256 a4ad8713f59e1bfee1a61ae636aefa36ab2b70bbdc4de2785c5217d2ea04c0a6 ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

Milestones and unconfirmed releases

Holder / event
Holder / eventTerm / dateConditions
Over-allotment windowPost-listing See filing · Additional shares only if exercisedOver-allotment window · Additional shares only if exercised
Insider resale eligibilityHolder-specific See 424B · Existing-holder supplyInsider resale eligibility · Existing-holder supply
Basis and evidence
Over-allotment window

Over-allotment window · Additional shares only if exercised

Lock-up / shares eligible for future sale ↗
Insider resale eligibility

Insider resale eligibility · Existing-holder supply

Lock-up / shares eligible for future sale ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Net income / (loss)

$ · Annual values as reported · Consolidated
FY2024($39,801,000)
FY2025($60,627,000)

Operating cash flow

$ · Annual values as reported · Consolidated
FY2024($35,035,000)
FY2025($59,199,000)
Financial quality
CalculationReported value
Cash and cash equivalents2024-12-31 · Consolidated$30,632,000
Cash and cash equivalents2025-12-31 · Consolidated$40,193,000
Current assets2024-12-31 · Consolidated$72,482,000
Current assets2025-12-31 · Consolidated$156,295,000
Total assets2024-12-31 · Consolidated$76,716,000
Total assets2025-12-31 · Consolidated$165,893,000
Current liabilities2024-12-31 · Consolidated$7,722,000
Current liabilities2025-12-31 · Consolidated$11,007,000
Total liabilities2024-12-31 · Consolidated$14,588,000
Total liabilities2025-12-31 · Consolidated$15,103,000
Total equity / (deficit)2024-12-31 · Consolidated($46,825,000)
Total equity / (deficit)2025-12-31 · Consolidated($107,436,000)
RevenueFY2025 · Consolidated$1,350,000
Net income / (loss)FY2024 · Consolidated($39,801,000)
Net income / (loss)FY2025 · Consolidated($60,627,000)
Operating cash flowFY2024 · Consolidated($35,035,000)
Operating cash flowFY2025 · Consolidated($59,199,000)
Cash and cash equivalents2025-12-31 · Consolidated · Unaudited$40,193,000
Cash and cash equivalents2026-03-31 · Consolidated · Unaudited$43,297,000
Current assets2025-12-31 · Consolidated · Unaudited$156,295,000
Current assets2026-03-31 · Consolidated · Unaudited$136,642,000
Total assets2025-12-31 · Consolidated · Unaudited$165,893,000
Total assets2026-03-31 · Consolidated · Unaudited$146,086,000
Current liabilities2025-12-31 · Consolidated · Unaudited$11,007,000
Current liabilities2026-03-31 · Consolidated · Unaudited$9,799,000
Total liabilities2025-12-31 · Consolidated · Unaudited$15,103,000
Total liabilities2026-03-31 · Consolidated · Unaudited$13,375,000
Total equity / (deficit)2025-12-31 · Consolidated · Unaudited($107,436,000)
Total equity / (deficit)2026-03-31 · Consolidated · Unaudited($125,515,000)
Net income / (loss)3M ended 2025-03-31 · Consolidated · Unaudited($15,151,000)
Net income / (loss)3M ended 2026-03-31 · Consolidated · Unaudited($18,656,000)
Operating cash flow3M ended 2025-03-31 · Consolidated · Unaudited($14,131,000)
Operating cash flow3M ended 2026-03-31 · Consolidated · Unaudited($18,141,000)
Basis and evidence
Cash and cash equivalents
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Cash and cash equivalents
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current assets
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total assets
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current liabilities
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total liabilities
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2024; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total stockholders’ deficit
December 31, 2025; consolidated; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total revenue
FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net loss
FY2024; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net loss
FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities
FY2024; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net cash used in operating activities
FY2025; consolidated; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Cash and cash equivalents
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Cash and cash equivalents
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current assets
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total assets
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current liabilities
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total liabilities
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total stockholders’ deficit
December 31, 2025; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
March 31, 2026; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Net loss
3M ended 2025-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Net loss
3M ended 2026-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Net cash used in operating activities
3M ended 2025-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Net cash used in operating activities
3M ended 2026-03-31; consolidated unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Saved snapshot — period not verified

These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.

Financial quality

Financial quality
CalculationReported valueReference
Revenue$1.35MNot meaningful
Net result$(64.13M)Latest reported
Market-value reference$895.00MPost-listing snapshot
Shares outstanding43.03MLatest reported
Offer size$289.00M17.000M
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Financial reviewReported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗
LATEST COMPARISON

Baseline filing — comparison pending

No source-comparable material changes identified in this report.

Open 424B4 ↗
Evidence 01Final prospectus source verified

Why it mattersChanges dilution, public float and potential supply.

Evidence · 424B4 · 2026/08/05
Evidence 02Trading began on 2026-08-05 at $17.00

Why it mattersChanges valuation, proceeds and first-day return assumptions.

Evidence · 424B4 · 2026/08/05
IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.
2026/08/05
424B4

• Final prospectus source verified

• Trading began on 2026-08-05 at $17.00

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

Potential impact
High
Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

Potential impact
High
Risk 4

Option exercise, employee equity and lock-up expiry can expand tradable supply.

Potential impact
Medium
Document424B4SEC source document
Filed2026-08-05SEC EDGAR
Research as of2026/08/051 public filings identified
Source-bound table inputs74SEC EDGAR
Open filing ↗
Sources and calculation notes

Final prospectus, offer price, listing date and headline financial evidence reconciled

View the filing's actual first page
Attovia Therapeutics, Inc. 424B4 first page
424B4 first pageFirst page from SEC EDGAR